Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 14/20 | 0.85 |
| ▸ | PRKAB1 | Q9Y478 | 14/20 | 0.85 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.85 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444396 | 0.95 | PRKAG1 (0.78) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1444309 | 0.92 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1444054 | 0.92 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL28534548 | 0.92 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL30341873 | 0.92 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1445129 | 0.89 | PRKAG1 (0.73) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1444598 | 0.89 | PRKAG1 (0.68) | PRKAG1PRKAB1PRKAA2PRKAA1CHRM5 | |
| SCHEMBL1444468 | 0.89 | PRKAG1 (0.71) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1444046 | 0.88 | PRKAG1 (0.76) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL28882505 | 0.86 | PRKAG1 (0.87) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | US | claimed |
| US-8778973-B2 | Alkene oxindole derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | claimed |
| US-20110071195-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | claimed |
| WO-2011032320-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | claimed |
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778973-B2 | Alkene oxindole derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778973-B2 | Alkene oxindole derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778973-B2 | Alkene oxindole derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2011033099-A1 | ALKENE OXINDOLE DERIVATIVES AND THEIR USES TO TREAT OBESITY, DIABETES AND HYPERLIPIDEMIA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071195-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071195-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071195-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2011032320-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011032320-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | PRKAB1, PRKAR2A, PRKAB2 | PRKAG1 5/4885PRKAB1 1/4885PRKAA2 12/4885 |
| US-20110071195-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | PRKAB1, PRKAR2A, PRKAB2 | PRKAG1 5/4885PRKAB1 1/4885PRKAA2 13/4885 |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | PRKAB1, PRKAR2A, PRKAB2 | PRKAG1 5/4885PRKAB1 1/4885PRKAA2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.